Drug – bio-affecting and body treating compositions – Effervescent or pressurized fluid containing – Organic pressurized fluid
Patent
1995-03-30
1998-11-03
Venkat, Jyothsna
Drug, bio-affecting and body treating compositions
Effervescent or pressurized fluid containing
Organic pressurized fluid
424 7837, 514851, A61K 912
Patent
active
058304363
ABSTRACT:
A method and medicament for the inhibition of oxidants comprising administering a treatment effective amount of alkylaryl polyether alcohol polymers to a chemical or biologic system in need thereof. Also, a method and medicament for mucociliary clearance, inhibition of cytokine production, and inhibition of interleukin-8 production in cystic fibrosis patients. The method involves administering a treatment effective amount of alkylaryl polyether alcohol polymers to a chemical or biologic system in need thereof. The medicament is preferably administered by aerosolization into the mammalian respiratory system. The medicament may also be applied to the mammalian skin. Preferably, the medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, isotonic saline, normal saline, petrolatum based ointments and U.S.P. cold cream.
REFERENCES:
patent: 2454541 (1948-11-01), Bock et al.
patent: 4039669 (1977-08-01), Beyler et al.
patent: 4826821 (1989-05-01), Clements
patent: 4944941 (1990-07-01), Ammann
patent: 5110806 (1992-05-01), Clements
patent: 5134129 (1992-07-01), Lichtenberger
patent: 5145684 (1992-09-01), Liversidge, et al.
patent: 5259963 (1993-11-01), Wiedemann
patent: 5399363 (1995-03-01), Liversidge, et al.
patent: 5474760 (1995-12-01), Ghio et al.
Lethem et al., "The Role of Mucous Glycoproteins in the Rheologic Properties of Cystic Fibrosis Sputum," Am. Rev. Respir. Dis., vol. 142, pp. 1053-1058 (1990).
Fuchs et al., "Effect of Aerosolized Recombinant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients with Cystic Fibrosis," The New England Journal of Medicine, vol. 331, pp. 637-642 (Sep., 1994).
Correspondence from Carolann W. Hooton, Chief, Freedom of Information Office, Food and Drug Administration, dated May 27, 1994.
Information brochure from Breon Laboratories on ALEVAIRE.RTM. describing the content and indicated use of this drug, dated Nov., 1965.
Aruoma, Deoxyribose Assay For Detecting Hydroxyl Radicals, Methods In Enzymology, vol. 233, pp. 57-82, (1994).
Baker et al., Development Of O2 Tolerance In Rabbits With No Increase In Antioxidant Enzymes, Journal of Applied Physiology, vol. 66, No. 4, pp. 1679-1684, (1989).
Cantin et al., Protection By Antibiotics Against Myeloperoxidase-Dependent Cytotoxicity To Lung Epithelial Cells In Vitro, The Journal of Clinical Investigation, Inc., vol. 91, pp. 38-45, (Jan. 1993).
Cornforth et al., Antituberculous Effect of Certain Surface-Active Polyoxyethyleen Ethers in Mice, Nature, vol. 168, pp. 150-153, (1951).
Floyd et al., Sensitive Assay of Hydroxyl Free Radical Formation . . . , Journal of Biochemical and Biophysical Methods, vol. 10, pp. 221-235, (1984).
Floyd et al., Use of Salicylate With High Pressure Liquid Chromatography . . . , Journal of Free Radicals in Biology & Medicine, vol. 2, pp. 12-18, (1986).
Fuchs et al., Effect Of Aerosolized Recombinant Human DNase On Exacerbations Of Respiratory Symptoms And On Pulmonary Function In Patients With Cystric Fibrosis, The New England Journal of Medicine, vol. 331, No. 10, pp. 637-642, (1994).
Ghio et al., Role Of Surface Complexed Iron In Oxidant Generation . . . , American Journal Of Physiology, Lung Cellular and Molecular Physiology 7, vol. 263, pp. L511-L518, (Jun. 29, 1992).
Ghio, Synthetic Surfactant Scavenges Oxidants And Protects Against Hyperoxic Lung Injury, Journal Of Applied Physiology, vol. 77, No. 3, pp. 1217-1223, (1994).
Glassman, Hemolytic Activity of Some Nonionic Surface-Active Agents, Science, vol. 111, pp. 688-689, (Jun. 23, 1950).
Robert A. Greenwald, Determination of HOCl Production by Micloperoxidase, CRC Handbook of Methods for Oxygen Radical Research, p. 300, (1987).
Halliwell et al., Role of Free Radicals . . . , Methods in Enzymology, vol. 186, pp. 1-83, (1990).
Hashimoto et al., Antimetastatic Effect Of Triton WR 1339, a Nonionic Detergent, On Rat Ascites Tumors, The Tohoku Journal Of Experimental Medicine, vol. 128, No. 3 pp. 259-265, (Jul. 1979).
Kim et al., Reevaluation Of The Effect Of Triton X-100 On The Assay Of Superoxide Radical By The Nitrobluetetrazolium Reduction Method, Hanguk Nonghwahak Hoechi (J. Korean Agric. Chem. Soc.), pp. 364-369, (1993).
Kondo et al., Triton WR-1339 As A Biological-Response Modifier In Mycobacterial Infection, Japan Journal Medical Science Biology, vol. 39, pp. 35-47, (1986).
Lethem, et al., The Role Of Mucous Glycoproteins In The Rheologic Properties Of Cystic Fibrosis Sputum, AAI Respiratory Disease, pp. 1063-1068, (1990).
Lowry et al., Protein Measurement With The Folin Phenol Reagent, Journal Of Biological Chemistry, vol. 193, pp. 265-275, (1951).
McCarty, An Antithrombotic Role For Nutritional Antioxidants: Implications For Tumor Metastasis And Other Pathologies, Med-Hypotheses, pp. 345-357, (Apr. 1986).
Matalon et al., Mitigation Of Pulmonary . . . Surfactant, Journal Of Applied Physiology, vol. 62, No. 2 . pp. 756-761, (Feb. 1987).
Palmer et al., The Effect Of An Aerosol Detergent In Chronic Bronchitis, The Lancet, pp. 611-613, (Mar. 23, 1957).
Pimm et al., Influence Of ICRF 159 and Triton WR 1339 On Metastases Of A Rat Epithelioma, The British Journal Of Cancer, vol. 31, No. 1, pp. 62-67, (Jan. 1975).
Polk et al., A Comparative Study Of Alevaire And A New Mucolytic Agent, Acumist In Postoperative Patients, The Eye, Ear, Nose and Throat Monthly, vol. 49, pp. 321-324, (Jul. 1970).
Notter, Biophysical Behavior . . . Pathophysiology, Seminars in Perinatology, vol. 12, No. 3, pp. 180-212, (Jul. 1988).
Ramsey et al., Efficacy Of Aerosolized Tobramycin In Patients With Cystic Fibrosis, The New England Journal Of Medicine, vol. 328, No. 24, pp. 1740-1746, (Jun. 17, 1993).
Tainter et al., Alevaire As A Mucolytic Agent, The New England Journal Of Medicine, vol. 253, pp. 764-767, (1955).
Thomassen, Regulation Of Human Alveolar Macrophage Inflammatory Cytokines By Tyloxapol: A Component Of The Synthetic Surfactant Exosurf, Clin. Immonol. Immunopathol., vol. 77, No. 2, pp. 201-205, (Nov. 1995).
Tooley et al., Lung Function . . . Surfactant, Am. Rev. Respir.-Dis., vol. 136, No. 3, pp. 651-656, (Sep. 1987).
Turrens et al., Protection Against Oxygen Toxicity, Journal of Clinical Investigation, vol. 73, pp. 87-95, (Jan. 1984).
Vasconcellos et al., Reduction In Viscosity Of Cystic Fibrosis Sputum In Vitro By Gelsolin, Science, vol. 263, pp. 969-971, (Feb. 18, 1994).
Wiseman et al., The Structural Mimicry Of Membrane Sterols By Tamoxifen: Evidence From Cholesterol Coefficients And Molecular-Modelling For Its Action As A Membrane Anti-Oxidant And An Anti-Cancer Agent, Biochim-Biophys-Acta., pp. 197-202, (Mar. 20, 1992).
Wiseman et al., Droloxifene (3-Hydroxytamoxifen) Has Membrane Antioxidant Ability: Potential Relevance To Its Mechanism Of Therapeutic Action In Breast Cancer, Cancer-Lett., pp. 61-68, (Sep. 14, 1992).
Correspondence from Carolann W. Hootan, Department Of Health & Human Services, regarding Alevaire, dated May 27, 1994, including brochure of Alevaire.RTM. dated Nov. 1965.
Ghio Andrew J.
Kennedy Thomas P.
Piantadcsi Claude A.
Duke University
Venkat Jyothsna
LandOfFree
Method of mucociliary clearance in cystic fibrosis patients usin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of mucociliary clearance in cystic fibrosis patients usin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of mucociliary clearance in cystic fibrosis patients usin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-686525